Abstract
Background: ROCKET AF and its East Asian subanalysis demonstrated that rivaroxaban was non-inferior to warfarin for stroke/systemic embolism (SE) prevention in patients with non-valvular atrial fibrillation (NVAF), with a favorable benefit–risk profile. XANAP investigated the safety and effectiveness of rivaroxaban in routine care in Asia-Pacific. Methods: XANAP was a prospective, real-world, observational study in patients with NVAF newly starting rivaroxaban. Patients were followed at ~3-month intervals for 1 year, or for ≥30 days after permanent discontinuation. Primary outcomes were major bleeding events, adverse events (AEs), serious AEs and all-cause mortality; secondary outcomes included stroke/SE. Major outcomes were adjudicated centrally. Results: XANAP enrolled 2273 patients from 10 countries: mean age was 70.5 years and 58.1% were male. 49.8% of patients received rivaroxaban 20 mg once daily (od), 43.8% 15 mg od and 5.9% 10 mg od. Mean treatment duration was 296 days, and 72.8% of patients had received prior anticoagulation therapy. Co-morbidities included heart failure (20.1%), hypertension (73.6%), diabetes mellitus (26.6%), prior stroke/non-central nervous system SE/transient ischemic attack (32.8%) and myocardial infarction (3.8%). Mean CHADS2, CHA2DS2-VASc and HASBLED scores were 2.3, 3.7 and 2.1, respectively. The rates (events/100 patient-years [95% confidence interval]) of treatment-emergent major bleeding, stroke and all-cause mortality were 1.5 (1.0-2.1), 1.7 (1.2-2.5) and 2.0 (1.4-2.7), respectively. Persistence was 66.2% at the study end. Conclusions: The real-world XANAP study demonstrated low rates of stroke and bleeding in rivaroxaban-treated patients with NVAF from Asia-Pacific. The results were consistent with the real-world XANTUS study and ROCKET AF.
| Original language | English |
|---|---|
| Pages (from-to) | 418-427 |
| Number of pages | 10 |
| Journal | Journal of Arrhythmia |
| Volume | 34 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2018 Jan 1 |
Fingerprint
Keywords
- Asia-pacific
- Bleeding risk
- Real world
- Rivaroxaban
- Stroke prevention
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
XANAP : A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in asia. / Kim, Young Hoon; Shim, Jaemin; Tsai, Chia Ti; Wang, Chun Chieh; Vilela, Gilbert; Muengtaweepongsa, Sombat; Kurniawan, Mohammad; Maskon, Oteh; Li Fern, Hsu; Nguyen, Thang Huy; Thanachartwet, Thititat; Sim, Kenneth; Camm, A. John.
In: Journal of Arrhythmia, Vol. 34, No. 4, 01.01.2018, p. 418-427.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - XANAP
T2 - A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in asia
AU - Kim, Young Hoon
AU - Shim, Jaemin
AU - Tsai, Chia Ti
AU - Wang, Chun Chieh
AU - Vilela, Gilbert
AU - Muengtaweepongsa, Sombat
AU - Kurniawan, Mohammad
AU - Maskon, Oteh
AU - Li Fern, Hsu
AU - Nguyen, Thang Huy
AU - Thanachartwet, Thititat
AU - Sim, Kenneth
AU - Camm, A. John
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Background: ROCKET AF and its East Asian subanalysis demonstrated that rivaroxaban was non-inferior to warfarin for stroke/systemic embolism (SE) prevention in patients with non-valvular atrial fibrillation (NVAF), with a favorable benefit–risk profile. XANAP investigated the safety and effectiveness of rivaroxaban in routine care in Asia-Pacific. Methods: XANAP was a prospective, real-world, observational study in patients with NVAF newly starting rivaroxaban. Patients were followed at ~3-month intervals for 1 year, or for ≥30 days after permanent discontinuation. Primary outcomes were major bleeding events, adverse events (AEs), serious AEs and all-cause mortality; secondary outcomes included stroke/SE. Major outcomes were adjudicated centrally. Results: XANAP enrolled 2273 patients from 10 countries: mean age was 70.5 years and 58.1% were male. 49.8% of patients received rivaroxaban 20 mg once daily (od), 43.8% 15 mg od and 5.9% 10 mg od. Mean treatment duration was 296 days, and 72.8% of patients had received prior anticoagulation therapy. Co-morbidities included heart failure (20.1%), hypertension (73.6%), diabetes mellitus (26.6%), prior stroke/non-central nervous system SE/transient ischemic attack (32.8%) and myocardial infarction (3.8%). Mean CHADS2, CHA2DS2-VASc and HASBLED scores were 2.3, 3.7 and 2.1, respectively. The rates (events/100 patient-years [95% confidence interval]) of treatment-emergent major bleeding, stroke and all-cause mortality were 1.5 (1.0-2.1), 1.7 (1.2-2.5) and 2.0 (1.4-2.7), respectively. Persistence was 66.2% at the study end. Conclusions: The real-world XANAP study demonstrated low rates of stroke and bleeding in rivaroxaban-treated patients with NVAF from Asia-Pacific. The results were consistent with the real-world XANTUS study and ROCKET AF.
AB - Background: ROCKET AF and its East Asian subanalysis demonstrated that rivaroxaban was non-inferior to warfarin for stroke/systemic embolism (SE) prevention in patients with non-valvular atrial fibrillation (NVAF), with a favorable benefit–risk profile. XANAP investigated the safety and effectiveness of rivaroxaban in routine care in Asia-Pacific. Methods: XANAP was a prospective, real-world, observational study in patients with NVAF newly starting rivaroxaban. Patients were followed at ~3-month intervals for 1 year, or for ≥30 days after permanent discontinuation. Primary outcomes were major bleeding events, adverse events (AEs), serious AEs and all-cause mortality; secondary outcomes included stroke/SE. Major outcomes were adjudicated centrally. Results: XANAP enrolled 2273 patients from 10 countries: mean age was 70.5 years and 58.1% were male. 49.8% of patients received rivaroxaban 20 mg once daily (od), 43.8% 15 mg od and 5.9% 10 mg od. Mean treatment duration was 296 days, and 72.8% of patients had received prior anticoagulation therapy. Co-morbidities included heart failure (20.1%), hypertension (73.6%), diabetes mellitus (26.6%), prior stroke/non-central nervous system SE/transient ischemic attack (32.8%) and myocardial infarction (3.8%). Mean CHADS2, CHA2DS2-VASc and HASBLED scores were 2.3, 3.7 and 2.1, respectively. The rates (events/100 patient-years [95% confidence interval]) of treatment-emergent major bleeding, stroke and all-cause mortality were 1.5 (1.0-2.1), 1.7 (1.2-2.5) and 2.0 (1.4-2.7), respectively. Persistence was 66.2% at the study end. Conclusions: The real-world XANAP study demonstrated low rates of stroke and bleeding in rivaroxaban-treated patients with NVAF from Asia-Pacific. The results were consistent with the real-world XANTUS study and ROCKET AF.
KW - Asia-pacific
KW - Bleeding risk
KW - Real world
KW - Rivaroxaban
KW - Stroke prevention
UR - http://www.scopus.com/inward/record.url?scp=85054738871&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054738871&partnerID=8YFLogxK
U2 - 10.1002/joa3.12073
DO - 10.1002/joa3.12073
M3 - Article
AN - SCOPUS:85054738871
VL - 34
SP - 418
EP - 427
JO - Journal of Arrhythmia
JF - Journal of Arrhythmia
SN - 1880-4276
IS - 4
ER -